2015 ACS GCI Pharmaceutical Roundtable Research Grant
News Aug 12, 2015
The ACS GCI Pharmaceutical Roundtable (Roundtable) is a partnership between the ACS Green Chemistry Institute® and pharmaceutical related corporations united by a shared commitment to integrate the principles of green chemistry and engineering into the business of drug discovery and production. Current members include Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Codexis, Dr. Reddy’s, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer Inc, Roche, Sanofi, and ACS GCI. In 2006, the Roundtable members conducted a survey that identified areas in need of focused research to advance the principles of green chemistry and their application in the pharmaceutical industry. Ten chemical transformations and two process related operations were identified and published (D.J. Constable, P.J. Dunn, et al., Key Green Chemistry Research Areas - a Perspective from Pharmaceutical Manufacturers, Green Chemistry, 2007, 9, 411 - 420). Following the green chemistry research areas, in 2011 the Roundtable members conducted a similar study to advance green engineering in the pharmaceutical industry. Ten green engineering research areas were identified and published (C. Jimenez-Gonzalez et al., Key green engineering research areas for sustainable manufacturing – a perspective from pharmaceuticals and fine chemicals, Org. Proc. Res. Dev., 2011, 15(4), 900-911.).
As efforts continue to support the outcomes of the survey, the Roundtable requests submission of proposals for development of Greener Continuous Chemistry & Engineering Technology. Areas of interest include, but are not limited to 1) photo redox chemistry, 2) photochemistry, and 3) biocatalysis in flow. Proposals will be accepted from public and private institutions of higher education worldwide. Up to three grants are planned to be awarded. Each award is limited to $50,000 for a grant period of 12 to 24 months. Proposals are due to the ACS GCI Pharmaceutical Roundtable on August 28, 2015 at 5 p.m. (EDT), no exceptions. Proposals received after the deadline will not be considered. Submissions must be a pdf file submitted via email to firstname.lastname@example.org
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE